Scholarlink

<p>Grade&#xa0;2 isocitrate dehydrogenase (IDH)-mutant gliomas are among the most common primary brain tumors in young adults and are characterized by slow but steady growth. Traditionally, postoperative management has consisted of MRI surveillance or radiotherapy/chemotherapy. Vorasidenib, an oral brain-penetrant dual inhibitor of mutant IDH1 and IDH2, has recently emerged as a&#xa0;targeted therapeutic option. In the randomized phase&#xa0;III INDIGO trial, treatment with vorasidenib significantly prolonged progression-free survival and delayed the need for subsequent therapeutic interventions in patients with residual or recurrent IDH-mutant grade&#xa0;2 gliomas after surgery alone. These findings expand the therapeutic landscape in the adjuvant setting with the aim of delaying tumor progression and postponing potentially neurotoxic standard treatments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Klinische Aspekte der Vorasidenib-Phase-III-Studie

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月15日

查看全文
  • Annette Leibetseder

摘要

Grade 2 isocitrate dehydrogenase (IDH)-mutant gliomas are among the most common primary brain tumors in young adults and are characterized by slow but steady growth. Traditionally, postoperative management has consisted of MRI surveillance or radiotherapy/chemotherapy. Vorasidenib, an oral brain-penetrant dual inhibitor of mutant IDH1 and IDH2, has recently emerged as a targeted therapeutic option. In the randomized phase III INDIGO trial, treatment with vorasidenib significantly prolonged progression-free survival and delayed the need for subsequent therapeutic interventions in patients with residual or recurrent IDH-mutant grade 2 gliomas after surgery alone. These findings expand the therapeutic landscape in the adjuvant setting with the aim of delaying tumor progression and postponing potentially neurotoxic standard treatments.